First Trust NASDAQ Cybersecurity ETF (NASDAQ: CIBR)

에 대한 최신 뉴스 First Trust NASDAQ Cybersecurity ETF (NASDAQ:CIBR)

First Trust NASDAQ Cybersecurity ETF

Technology

Industrials

To achieve its investment objectives, The Nasdaq CTA Cybersecurity Index is designed to track the performance of companies engaged in the cybersecurity segment of the technology and industrials sectors. It includes companies primarily involved in the building, implementation, and management of security protocols applied to private and public networks, computers, and mobile devices in order to provide protection of the integrity of data and network operations.

Broadcom, Inc. (purchase Right At $290.00 Per Share) (5)

Crowdstrike Holdings Inc

Cisco Systems, Inc.

Palo Alto Networks Inc.

Infosys, Adr

Darktrace Plc

Thales S.A.

Gen Digital Inc

Leidos Holdings, Inc.

Booz Allen Hamilton Holding Corp.

Cloudflare Inc

Check Point Software Technologies Ltd.

Fortinet, Inc.

Cyberark Software

Okta Inc.

Zscaler  Inc .

Wiz,And,Alphabet,Company,Logos,Seen,On,The,Smartphone,And

Sector ETFs

Tech

ETFs

AMZN

CIBR

GOOGL

HACK

MSFT

구글의 모회사 알파벳(NASDAQ:GOOGL)이 클라우드 사이버보안 스타트업인 위즈(Wiz)를 인수하기 위해 320억 달러를 지불한다. 이는 알파벳으로서는 기록적인 거래 규모다.이번 위즈 거래는 구글 클라우드의 파워 플레이가 아니라 전체 사이버보안 부문을 뒤엎고 클라우드 컴퓨팅, 사이버보안, 대형주 기술에 투자하는 ETF에 새로운 활력을 불어넣을 수 있다. 

알파벳의 사이버보안 베팅 속 잭팟 기대할 만한 ETF 3종목

davos shutter2

News

Specialty ETFs

Emerging Market ETFs

Global

ANEW

AVGO

CRWD

CSCO

ENPH

FFIV

FITE

FSLR

iShares Dow Jones US Aerospace & Defense Index Fund

VSAT

세계경제포럼(WEF)의 2025년 &#39;글로벌 리스크 보고서&#39;는 앞으로의 도전 과제에 대한 냉정한 그림을 보여 준다. 스위스 다보스에서 열린 WEF 연례 회의에서 발표된 이번 설문조사는 지정학적 긴장, 기후 변화, 허위 정보에 대한 리스크를 강조한다.

2025년 WEF 글로벌 리스크 보고서: 지정학적 긴장, 기후 변화 및 사이버 리스크에 대응하는 ETF는?

tap-791172_1280

Asia

IHAK

WCBR

중국 정부의 지원을 받는 해커들이 미국의 중요한 인프라에 &#39;대혼란&#39;을 일으킬 수 있는 지능형 공격을 조율하고 있다고 미국 연방수사국(FBI) 국장인 크리스토퍼 레이(Christopher Wray)가 밝혔다. 그는 목요일 내슈빌에서 열린 현대 분쟁에 관한 서밋(Summit on Modern Conflict)에서 참석자들에게 &#34;수처리 시설과 에너지 그리드부터 교통 및 정보 기술에 이르기까지 모든 것이 우리 사회의 중추를 형성한다&#34;고 말했다.

中 해커가 美의 주요 인프라에 &#39;대혼란&#39;을 일으킬  수 있다고 FBI가 경고 - 주목해야 할 스타트업 3곳

Biotech

General

ALZN

Alzamend Neuro Doses First Patient In Phase II Clinical Trial of AL001

Easily one of the most dominant enterprises in recent memory is Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>). A big data analytics specialist, Palantir has been a massive beneficiary of the boom in artificial intelligence. Since the start of this year, PLTR stock has gained nearly 64% of equity value, easily leapfrogging the Nasdaq Composite index, which is down 1% during the same period. Still, valuation concerns impose a dark cloud over PLTR's prospects.
On the business front, it's difficult to argue against Palantir's dominance, especially in the realm of the defense industry. Recently, PLTR stock popped higher thanks to the Department of Defense awarding the underlying company a<a href="https://www.benzinga.com/25/05/45572000/palantir-stock-is-trading-higher-thursday-whats-going-on"> $795 million modification</a> to a contract for its Maven Smart System software licenses.
Initially, the deal was announced last year as a $480 million fixed, firm-price contract. However, with the modification, the terms of the agreement bring the total contract value up to nearly $1.28 billion. Fundamentally, the upgrade demonstrates the core influence that Palantir has achieved in its primary market.
In addition, Palantir is making significant inroads into the commercial sector. Notably, the company's Artificial Intelligence Platform (AIP) is gaining traction, allowing it to partner with major corporations. Indeed, Wedbush analyst Dan Ives believes that PLTR stock will command a<a href="https://www.benzinga.com/25/05/45232694/palantir-stock-shows-momentum-with-q1-results-ai-opportunity-analyst-says-generation-tech-name-worth-1-trillion-in-future"> trillion-dollar market capitalization</a> over the next three years.
Still, not everyone is convinced about Palantir's stratospheric run. One of the most notable criticisms centers on<a href="https://www.macrotrends.net/stocks/charts/PLTR/palantir-technologies/pe-ratio"> valuation</a>. As of this moment, PLTR stock trades at over 538-times trailing-12-month earnings. About a year ago, this metric was around 149 times – which was still a lofty figure. The anxiety, then, is that early investors will head for the exits.
This isn't just an empty sentiment. This year, the predominant transaction type among<a href="https://www.benzinga.com/quote/PLTR/insider-trades"> insider activity</a> for PLTR stock was sell orders, either for the equity or its options. To be fair, insiders sell stock for a variety of reasons, many of them mundane. Nevertheless, it's not the most encouraging sign when insiders – the folks that know the business the best – head for the exits.
The Direxion ETFs: While the trajectory of PLTR stock this year has been largely one-sided, there's more than enough room for skepticism – and that suits financial services provider Direxion perfectly. Thanks to its PLTR-focused bull and bear exchange-traded funds, traders can easily speculate on the tech specialist's fortunes (or misfortunes).
For the optimists, they may consider the Direxion Daily PLTR Bull 2X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTU#NASDAQ">PLTU</a>), which seeks the daily investment results, before fees and expenses, of 200% of the performance of PLTR stock. Conversely, the pessimists may be intrigued by the Direxion Daily PLTR Bear 1X Shares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTD#NASDAQ">PLTD</a>), which tracks 100% of the inverse performance of the namesake equity.
Primarily, the main functionality of these specialized ETFs is to offer convenient mechanisms for speculation. Typically, those interested in utilizing leverage or engaging in short positions must trade options. While derivative financial instruments offer incredible flexibility, they're also complex vehicles with unique risk-reward profiles. With Direxion ETFs, the units can be bought and sold much like any other public security, thus easing the learning curve.
Still, there are serious risks to consider. First, both leveraged and inverse ETFs tend to be more volatile than standard bread-and-butter funds. Second, PLTU and PLTD were designed for exposure lasting no longer than one day. Holding onto these funds for longer than the recommended period may lead to value decay due to the daily compounding effect.
The PLTU ETF: Since the start of this year, the Direxion Daily PLTR Bull 2X Shares nearly doubled in value thanks to the robust performance of PLTR stock.
<ul class="wp-block-list">
<li>Currently, technical momentum in the PLTU ETF is robust, with the bull fund above both its 50-day moving average (DMA) and its 20-day exponential moving average (EMA).</li>
<li>One concern to note is that May's rising price action has been met with declining volume. Ideally, rising volume should confirm rising price, thus warranting caution.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1037" height="618" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382.png" alt="" class="wp-image-931425" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382.png 1037w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-768x471.png 768w" sizes="(max-width: 1037px) 100vw, 1037px" /></figure>
The PLTD ETF: Predictably, the year-to-date performance of the Direxion Daily PLTR Bear 1X Shares has been poor, with the bear fund losing more than 54%.
<ul class="wp-block-list">
<li>In a picture of contrasts, the PLTD ETF is conspicuously below both its 50 DMA and its 20 EMA, reflecting deep pessimism.</li>
<li>At the same time, the inverse fund is attempting to develop a baseline at the $10.50 level. If so, a quick reversal toward the $11 mark isn't out of the question.</li>
</ul>
<figure class="wp-block-image"><img loading="lazy" decoding="async" width="1036" height="635" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382.png" alt="" class="wp-image-931426" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382.png 1036w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-300x184.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-1024x628.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/29075921/image-382-768x471.png 768w" sizes="(max-width: 1036px) 100vw, 1036px" /></figure>
Featured image by <a href="https://pixabay.com/users/thedigitalartist-202249/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7186533">Pete Linforth</a> from <a href="https://pixabay.com/illustrations/big-data-data-information-binary-7186533/">Pixabay</a>.

Long Ideas

Short Ideas

Technicals

Trading Ideas

PLTD

PLTR

PLTU

Productivity Clashes With Premium Valuations For Direxion's PLTR-Focused Bull And Bear Funds

<ul>
<li>CC-42344 was shown to be highly active against the highly pathogenic 2024 Texas H5N1 avian influenza strain</li>
<li>The Company's virology study further confirmed the previous structural and in vitro data that revealed the binding of CC-42344 to PB2 protein of the 2024 H5N1 avian influenza virus</li>
</ul>
BOTHELL, Wash., May 29, 2025 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=a2lvSGEYfO0wnqCxWhGN5Th2eyiuG47RucIAbJQEGzvjuCfbXbv1Ec0_EkxdTb7h66djGR5DLGdfjb8IPoG_D23fZs9axyH_vboP8qCGanQ=">Cocrystal Pharma, Inc</a>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCP#NASDAQ">COCP</a>) announces that a recent virology study showed its novel, broad-spectrum influenza PB2 inhibitor CC-42344 exhibits strong antiviral activity against the highly pathogenic H5N1 avian influenza A strain (A/Texas/37/2024).
On March 25, 2024, the highly pathogenic avian H5N1 influenza virus was confirmed in a dairy cow in Texas and has continued to spread widely in U.S. dairy cattle, causing a few human cases. There is concern that the H5N1 virus could adapt for human-to-human transmission and potentially result in an influenza pandemic. CC-42344 is a new investigational drug candidate for the treatment of pandemic and seasonal influenza infections. This inhibitor binds to a highly conserved active site of the PB2 protein and inhibits the viral replication process. The Company previously announced the structural and in vitro data of CC-42344 with the purified H5N1 PB2 protein.
The virology study utilized the highly pathogenic H5N1 avian strain (influenza A/Texas/37/2024) and was conducted to test antiviral activity of CC-42344 using Tamiflu&#xAE; as a reference inhibitor. The data showed that CC-42344 was highly potent against the H5N1 avian influenza virus (EC50, 0.003 µM), approximately 1,000-fold more potent, compared to a refence compound Tamiflu (EC50, 2.69 µM). CC-42344 is currently in development as an oral treatment for pandemic avian and seasonal influenza A infections with initial data showing a favorable safety and tolerability profile.

COCP

Cocrystal Pharma's Recent Virology Study Shows Broad-Spectrum Influenza PB2 Inhibitor CC-42344 Exhibits Strong Antiviral Activity Against Highly Pathogenic H5N1 Avian Influenza A Strain

Media

PODC

PodcastOne Acquires New Podcasts, Marking 11 Additions In 2025

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.RevBiosciences.com&amp;esheet=54261915&amp;newsitemid=20250529009291&amp;lan=en-US&amp;anchor=Revelation+Biosciences%2C+Inc.&amp;index=1&amp;md5=9e09ccbaa4de8f68db344a0670de27f0">Revelation Biosciences, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation to optimize health, today announced the pricing of a public offering of 3,640,000 shares of its common stock (or common stock equivalents), together with warrants to purchase up to 14,560,000 shares of its common stock at an offering price to the public of $1.10 per share and associated warrant. The warrants will have an exercise price of $1.10 per share, are exercisable beginning on the effective date of stockholder approval of the issuance of the shares upon exercise of the warrants, and will expire five years following the initial exercise date. The closing of the offering is expected to occur on or about May 29, 2025, subject to the satisfaction of customary closing conditions.
Roth Capital Partners is acting as sole placement agent for the offering.
The gross proceeds to the Company from the offering are expected to be approximately $4 million, before deducting the placement agent's fees and other offering expenses payable by Revelation. The Company intends to use the net proceeds from this offering to further the development of our product candidates, including (i) the completion of our ongoing Phase 1b clinical study, (ii) the manufacture of clinical drug supply, (iii) additional preclinical work for multiple indications, (iv) continue to develop other products and therapies, and (v) fund working capital and general corporate purposes using any remaining amounts.
&nbsp;

Offerings

REVB

Revelation Biosciences Announces Pricing Of $4M Public Offering Of Up To 14.56M Shares AT An Offering Price Of $1.10/Shr

NextDecade Corporation (NextDecade or the Company) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) announced today that it has executed a 20-year liquefied natural gas (LNG) sale and purchase agreement (SPA) with JERA for offtake from Train 5 at the Rio Grande LNG Facility.
Under the terms of the SPA, JERA will purchase 2.0 million tonnes per annum (MTPA) of LNG for 20 years on a free on board basis at a price indexed to Henry Hub, subject to a positive Final Investment Decision (FID) on Train 5.
Achieving a positive FID on Train 5 will be subject to, among other things, entering into appropriate commercial arrangements, entering into an engineering, procurement, and construction agreement, and obtaining adequate financing to construct Train 5 and related infrastructure.

NextDecade Executes 20-Year Liquefied Natural Gas Sale And Purchase Agreement With JERA For Offtake From Train 5 At Rio Grande LNG Facility

In the preceding three months, 12 analysts have released ratings for Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>), presenting a wide array of perspectives from bullish to bearish.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">10</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Macy's, presenting an average target of $13.33, a high estimate of $17.00, and a low estimate of $8.00. Experiencing a 12.19% decline, the current average is now lower than the previous average price target of $15.18. 
<img src="https://www.benzinga.com/files/images/story/2025/1748520077_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Macy's. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Alex Straton</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Paul Kearney</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>-</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$13.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$15.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$16.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$17.00</td>
<td>$19.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Sell</td>
<td>$8.00</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Market Perform</td>
<td>$15.00</td>
<td>$17.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Market Perform</td>
<td>$17.00</td>
<td>$17.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Macy's. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Macy's compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Macy's's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Macy's's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/M/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Macy's analyst ratings.</a>
<h2>Unveiling the Story Behind Macy's</h2>
Founded in 1858 and based in New York City, Macy's operates about 450 stores under the Macy's nameplate, nearly 60 stores under the Bloomingdale's (full-price and outlet) and Bloomie's nameplates, and more than 170 freestanding Bluemercury specialty beauty stores. Macy's also operates e-commerce sites and licenses Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances constitute about 62% of Macy's sales.
<h3>Macy's's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Challenges: Macy's's revenue growth over 3M faced difficulties. As of 31 January, 2025, the company experienced a decline of approximately -4.39%. This indicates a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 4.27%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 7.86%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Macy's's ROA excels beyond industry benchmarks, reaching 2.03%. This signifies efficient management of assets and strong financial health.
Debt Management: Macy's's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.25, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>How Are Analyst Ratings Determined?</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

Breaking Down Macy's: 12 Analysts Share Their Views

In the latest quarter, 9 analysts provided ratings for Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>), showcasing a mix of bullish and bearish perspectives.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target of $32.67, a high estimate of $68.00, and a low estimate of $10.00. Highlighting a 23.0% decrease, the current average has fallen from the previous average price target of $42.43. 
<img src="https://www.benzinga.com/files/images/story/2025/1748520054_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
The standing of Intellia Therapeutics among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>David Nierengarten</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Debjit Chattopadhyay</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>David Lebowitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Geulah Livshits</td>
<td>Chardan Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$68.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Andy Chen</td>
<td>Wolfe Research</td>
<td>Announces</td>
<td>Outperform</td>
<td>$21.00</td>
<td>-</td>
</tr>
<tr>
<td>Mitchell Kapoor</td>
<td>HC Wainwright &amp; Co.</td>
<td>Announces</td>
<td>Buy</td>
<td>$30.00</td>
<td>-</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$50.00</td>
<td>$90.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intellia Therapeutics. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intellia Therapeutics compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intellia Therapeutics's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/NTLA/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Intellia Therapeutics analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Intellia Therapeutics's Background</h2>
Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
<h3>Unraveling the Financial Story of Intellia Therapeutics</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Decline in Revenue: Over the 3M period, Intellia Therapeutics faced challenges, resulting in a decline of approximately -42.54% in revenue growth as of 31 March, 2025. This signifies a reduction in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -687.61%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of -13.84%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Intellia Therapeutics's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -10.5%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.15.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NTLA

Demystifying Intellia Therapeutics: Insights From 9 Analyst Reviews

Ratings for C3.ai (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AI#NYSE">AI</a>) were provided by 3 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated C3.ai and provided 12-month price targets. The average target is $18.33, accompanied by a high estimate of $20.00 and a low estimate of $17.00. This current average has decreased by 27.64% from the previous average price target of $25.33. 
<img src="https://www.benzinga.com/files/images/story/2025/1748520041_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive C3.ai. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$17.00</td>
<td>$21.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$20.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$18.00</td>
<td>$25.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to C3.ai. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of C3.ai compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of C3.ai's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of C3.ai's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/AI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on C3.ai analyst ratings.</a>
<h2>Unveiling the Story Behind C3.ai</h2>
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.
<h3>Key Indicators: C3.ai's Financial Health</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: C3.ai's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 26.0%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Information Technology sector.
Net Margin: C3.ai's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -81.19%, the company may face hurdles in effective cost management.
Return on Equity (ROE): C3.ai's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -9.33%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): C3.ai's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -7.63%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: C3.ai's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 3 Analyst Projections For C3.ai

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) underwent analysis by 10 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $255.2, a high estimate of $300.00, and a low estimate of $201.00. This upward trend is apparent, with the current average reflecting a 1.43% increase from the previous average price target of $251.60.
<img src="https://www.benzinga.com/files/images/story/2025/1748520028_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Veeva Systems. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$300.00</td>
<td>$270.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$255.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Sangita Jain</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$249.00</td>
<td>$218.00</td>
</tr>
<tr>
<td>Allan Verkhovski</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$245.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Craig Hettenbach</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$201.00</td>
<td>$195.00</td>
</tr>
<tr>
<td>Joe Meares</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$217.00</td>
<td>$210.00</td>
</tr>
<tr>
<td>Jeff Garro</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$280.00</td>
<td>$280.00</td>
</tr>
<tr>
<td>Joe Vruwink</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$285.00</td>
<td>$283.00</td>
</tr>
<tr>
<td>Ryan MacDonald</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$270.00</td>
<td>$270.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Veeva Systems. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Veeva Systems compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Veeva Systems's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Veeva Systems's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/VEEV/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Veeva Systems analyst ratings.</a>
<h2>Discovering Veeva Systems: A Closer Look</h2>
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
<h3>A Deep Dive into Veeva Systems's Financials</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Veeva Systems's revenue growth over a period of 3M has been noteworthy. As of 31 January, 2025, the company achieved a revenue growth rate of approximately 14.31%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 27.14%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Veeva Systems's ROE stands out, surpassing industry averages. With an impressive ROE of 3.45%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Veeva Systems's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.84%, the company showcases efficient use of assets and strong financial health.
Debt Management: Veeva Systems's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.01.
<h2>Analyst Ratings: Simplified</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VEEV

10 Analysts Assess Veeva Systems: What You Need To Know

Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) raises FY2026 Adj EPS guidance from $7.32 to $7.63 vs $7.30 analyst estimate. Raises FY2026 sales outlook from $3.04 billion-$3.06 billion to $3.09 billion-$3.10 billion vs $3.06 billion estimate.

Guidance

Reported Earlier, Veeva Systems Raises FY2026 Adj EPS Guidance from $7.32 to $7.63 vs $7.30 Est; Raises FY2026 Sales Guidance from $3.04B-$3.06B to $3.09B-$3.10B vs $3.06B Est

RBC Capital analyst Rishi Jaluria downgrades Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) from Outperform to Sector Perform and lowers the price target from $420 to $275.

Downgrades

Price Target

RBC Capital Downgrades Salesforce to Sector Perform, Lowers Price Target to $275

Management

Koppers Holdings Appoints James A. Sullivan President; Effective June 1, 2025

ALMS

Alumis Completes Patient Enrollment In Pivotal Phase 3 ONWARD Clinical Program Of ESK-001 For Treatment Of Moderate-To-Severe Plaque Psoriasis

President Donald Trump has been dealt a significant blow to his trade policies, with a federal court ruling against his authority to impose global tariffs. However, the president is likely to find a workaround to this setback.
What Happened: Goldman Sachs economists believe that the court&#8217;s decision will only be a temporary obstacle, as the Trump administration has other legal ways of imposing tariffs. These include Section 122 of the Trade Act of 1974, Section 301 investigations and Section 338 of the Trade Act of 1930, <a href="https://www.cnbc.com/2025/05/29/trump-expected-to-find-a-workaround-after-trade-court-blocks-tariffs.html">reported</a> CNBC.
Section 122 allows the administration to swiftly impose tariffs—up to 15%—without a formal investigation, offering a quick workaround to court obstacles. However, Goldman analysts note the measure would expire after 150 days unless Congress intervenes.
Meanwhile, Section 232 tariffs on steel, aluminum, and autos may be expanded to other sectors, while Section 338 permits the president to impose up to 50% tariffs on imports from countries that discriminate against the U.S.
The White House could shift its focus from targeting specific countries to targeting industries instead — an approach that rests on more solid legal footing, as per Goldman Sachs.
Steven Blitz, TS Lombard&#8216;s chief U.S. economist, opined, "The first thing he will probably do is an emergency appeal to the Supreme Court … wanting to get a ruling from them that basically says you can keep these tariffs in place while the appeals process runs through."
Speaking about the Trump Administration&#8217;s appeal within minutes, Deutsche Bank's Jim Reid said a note, "We should say at the outset that this is hardly the end of this story,&#8221; reported Fortune. 
SEE ALSO: <a href="https://benzinga.com/25/05/45664572/us-stocks-likely-to-open-higher-after-federal-court-invalidates-trumps-tariffs-without-tariff-revenues-there-is-a-big-beautiful-hole-in-the-big-beautiful-budget-bill-says-expert" target="_blank" rel="noreferrer noopener">US Stocks Likely To Open Higher After Federal Court Blocks Trump&#8217;s Tariffs: &#8216;Without Tariff Revenues, There Is A Big Beautiful Hole In The Big Beautiful Budget Bill,&#8217; Says Expert</a>
Why It Matters: The court&#8217;s ruling could have a significant impact on the administration&#8217;s trade strategies. The decision, delivered by the U.S. Court of International Trade, could potentially <a href="https://www.benzinga.com/news/25/05/45660322/trump-tariffs-struck-down-by-federal-court-major-blow-to-white-houses-trade-strategy-report">halt </a>the administration&#8217;s trade war efforts.
Legal experts and economists have supported the court&#8217;s decision stating that the President was wrong to claim a virtually unlimited power to impose tariffs. However, some economists in the past stated that Trump tariffs are &#8216;addictive&#8217; and could remain in place even if the Democrats come <a href="https://www.benzinga.com/news/25/05/45556999/addictive-trump-tariffs-are-here-to-stay-even-if-democrats-come-back-to-power-says-wharton-professor">back to power</a> as they may not want to discontinue the lucrative revenue stream. 
Meanwhile, China has already responded to the court&#8217;s decision, calling on the United States to <a href="https://www.benzinga.com/markets/25/05/45664337/china-tells-us-to-entirely-revoke-wrongful-unilateral-tariffs-after-court-blocks-trumps-liberation-day-levies">entirely withdraw</a> the unilateral tariff measures that the court blocked.
Despite the setback, Trump is expected to find a way around the court&#8217;s ruling, potentially using other legal means to impose tariffs. The market reaction to the ruling has been mixed, with equity&nbsp;markets around the world broadly&nbsp;rising, while the reaction in Europe has been more muted.
During Thursday&#8217;s pre-market, The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and  Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 1.06% and 1.55%, respectively.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/25/05/45661076/peter-schiff-challenges-jd-vances-bitcoins-safe-haven-assertion-urges-him-to-implement-policies-that-reduce-the-need-to-hedge" target="_blank" rel="noreferrer noopener">JD Vance Said Bitcoin Created Wealth, Peter Schiff Says It Did No Such Thing: &#8216;What Has Happened Is A Massive Transfer Of …&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

'Hardly The End Of This Story:' Trump Has Several Legal Options To Maintain Tariffs Despite Federal Court Ruling, Experts Say

WGRX

Wellgistics Health Announces Preliminary Inclusion In Russell 2000 And Russell 3000 Indexes, As Part Of 2025 Russell US Indexes Annual Reconstitution

<ul>
<li>Strategic Expansion into Turkiye: DeFi Technologies enters collaboration with Misyon Bank and Misyon Kripto to work to introduce ETPs, offering Turkish investors alternative access to digital assets like Bitcoin and Ethereum.</li>
<li>Tapping a High-Growth Market: Turkiye ranks among the top countries in crypto adoption, driven by inflation, currency volatility, and a digitally native population, with over 50% of investor population holding digital assets.</li>
<li>Global Growth Momentum: The partnership aligns with DeFi Technologies' broader strategy to expand across the Middle East, Asia, and Africa through key institutional partnerships and localized product offerings.</li>
</ul>
&nbsp;"DeFi Technologies"(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DEFT#NASDAQ">DEFT</a>) (CBOE CA: DEFI) (GR: R9B), a financial technology company bridging the gap between traditional capital markets and decentralized finance ("DeFi"),&nbsp; and its subsidiary Valour Inc. ("Valour"), a leading issuer of exchange traded products ("ETPs") that provide simplified access to digital assets, is pleased to announce its strategic collaboration with Misyon Bank and its crypto trading subsidiary Misyon Kripto prepare for introducing a series of innovative digital investment products to Turkish investors.

Contracts

DEFT

DeFi Technologies And Misyon Enters Agreement To Launch Innovative Digital Asset Investment Products In Turkiye

STRM

Trading Halt: Halted at 7:55:00 a.m. ET - Trading Halt: Halt News Pending

One of the major dealers of Chinese EV giant BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) has reportedly shut down its operations across multiple cities in China as the company expands into the European market.
What Happened: Over 20 stores of Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) rival in China's eastern Shandong province, owned by a company called Qiancheng Holdings, were shut, according to a Reuters report citing Chinese state-owned media on Thursday.
The company shutting down the stores in over 4 major cities has affected over 1,000 customers with warranty and after-sales service-related woes, the report suggests.
Qiancheng cited changes to BYD's dealer policies, which increased the pressure on the company's cash flow. However, a representative from BYD cited in the Reuters report suggests that Qiancheng's rapid expansion led to the crisis instead.
BYD did not immediately respond to <a href="http://pro.benzinga.com">Benzinga&#8217;s</a> request for comment.
Why It Matters: BYD has been steadily expanding its footprint on the global front, with the automaker setting up <a href="https://www.benzinga.com/25/04/45097773/satellite-images-put-tesla-rival-byds-hungarian-factory-capable-of-producing-200k-units-annually-in-the-spotlight">a manufacturing facility</a> in Hungary, which can annually produce over 200,000 EVs.
BYD <a href="https://www.benzinga.com/25/05/45564693/byd-outsells-elon-musks-tesla-amid-european-plans-shift-into-gear">also overtook Tesla </a>for the first time in sales in the European market, registering marginally better sales in April 2025 than Elon Musk's company.
However, the Chinese automaker has recently landed in legal trouble as BYD faces a <a href="https://www.benzinga.com/government/regulations/25/05/45639357/teslas-chinese-rival-byd-sued-for-45-million-over-alleged-human-trafficking-slave-like-conditions-at-brazil-factory-site">$45 million lawsuit</a> in Brazil for alleged "human-trafficking" and "slave-like" conditions at the construction site in Brazil's Bahia state.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/asia/25/05/45611701/chinese-regulators-will-meet-tesla-rival-byd-other-companies-to-discuss-zero-mile-used-cars-report">Chinese Regulators Will Meet Tesla Rival BYD, Other Companies To Discuss &#8216;Zero Mile&#8217; Used Cars: Report</a></li>
</ul>
Photo courtesy: Tada Images/Shutterstock

BYDDY

TSLA

Over 20 BYD Dealerships Shut Down In China Amid Expansion To Europe, Impacting 1,000+ Customers: Report

QNTM

Quantum Biopharma Licensee Celly Nutrition Changes Name To Unbuzzd Wellness Inc. Effective May 23, 2025

구글의 모회사 알파벳(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)이 클라우드 사이버보안 스타트업인 위즈(Wiz)를 인수하기 위해 320억 달러를 지불한다. 이는 알파벳으로서는 <a href="https://www.benzinga.com/tech/25/03/44376743/google-parent-alphabet-to-acquire-wiz-in-32-billion-deal-its-biggest-bet-yet" target="_blank" rel="noopener">기록적인 거래 규모다.</a>
이번 위즈 거래는 구글 클라우드의 파워 플레이가 아니라 전체 사이버보안 부문을 뒤엎고 클라우드 컴퓨팅, 사이버보안, 대형주 기술에 투자하는 <a href="https://www.benzinga.com/etfs" target="_blank" rel="noopener">ETF</a>에 새로운 활력을 불어넣을 수 있다.
이러한 파도 속에서 3가지 ETF가 혜택을 볼 수 있다. 바로 Amplify Cybersecurity ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HACK#NYSE">HACK</a>), First Trust NASDAQ Cybersecurity ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIBR#NASDAQ">CIBR</a>) 그리고 Global X Cybersecurity ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUG#NASDAQ">BUG</a>)이다.
<ul>
<li>Amplify Cybersecurity ETF: HACK은 나스닥 ISE 사이버보안 셀렉트 지수(Nasdaq ISE Cyber Security Select Index)를 추종하며 25개 종목을 보유한다.. 알파벳은 핵심 종목은 아니지만 사이버보안 분야의 M&amp;A 루머가 ETF 전체에 상승을 이끌 수 있다. HACK의 운용자산은 20억1천만 달러이며 연간 수수료는 0.60%를 부과한다. 흥미로운 점은 <a style="font-size: revert;" href="https://www.benzinga.com/topic/cybersecurity" target="_blank" rel="noopener">사이버보안 분야</a>에만 투자하는 최초의 ETF라는 것이다.</li>
<li>First Trust NASDAQ Cybersecurity ETF: CIBR은 나스닥 CTA 사이버보안 지수(Nasdaq CTA Cybersecurity Index)를 추적하며, 사이버보안 분야의 32개 종목을 보유하고 있다. 운용자산은 80억 3천만 달러이며, 밸류에이션이 상승하고 거래 투기가 증가할 수 있다. 수수료는 연간 0.59%이다.</li>
<li>Global X Cybersecurity ETF: BUG는 사이버보안 솔루션에 대한 수요 증가로 이익을 얻을 수 있는 기업에 투자한다. 네트워크 보안, 클라우드 보호, 사이버 방어 서비스에 중점을 둔 28개의 주식을 보유하며 Indxx 사이버보안 지수(Indxx Cybersecurity Index)를 추종한다. 8억 9,170만 달러의 자산을 관리하고 있는 BUG는 연 0.50%의 수수료를 부과한다. 클라우드 보안의 중요성이 높아짐에 따라 이 ETF는 알파벳의 위즈 인수로 업계에 더 많은 관심이 집중되면서 강력한 모멘텀을 경험할 수 있다.</li>
</ul>
<h3 class="wp-block-heading">알파벳이 위즈에 올인한 이유는?</h3>
위즈는 평범한 사이버보안 회사가 아니다. 가장 빠르게 성장하는 클라우드 보안 브랜드 중 하나다다. 2020년에 설립되었으며, 증가하는 사이버 위협에 대처해야 할 필요성이 커짐에 따라 점점 더 중요해지고 있는 클라우드 환경의 취약점을 탐지할 수 있도록 지원한다. 사이버 공격이 점점 더 일반화되고 복잡해지면서 기업들은 클라우드 보안에 대해 그 어느 때보다 많은 관심을 기울이고 있다.
알파벳의 경우, 이번 인수로 보안 제품에 막대한 투자를 해온 아마존의 AWS와 마이크로소프트의 애저라는 강력한 경쟁자들에 맞서 구글 클라우드의 입지를 강화할 수 있게 되었다.
또한 사이버보안 M&amp;A가 <a href="https://www.privateequityinternational.com/cybersecurity-sparks-back-to-life/" target="_blank" rel="noopener">증가하고 있는 시점</a>에 이루어졌다. 현 정부 들어 규제 환경이 더 우호적으로 바뀔 것으로 예상되는 가운데, 이번 계약은 이 분야에서 더 많은 대형 거래의 시작에 불과할 수 있다.
알파벳의 위즈 인수는 사이버보안 M&amp;A의 새로운 물결의 빙산의 일각이 될 수 있다. 사이버 공간의 위협이 날로 증가함에 따라 클라우드 보안은 대부분의 기업에서 최우선 과제로 남아 있다.
사이버보안이 기술 투자의 주요 트렌드로 부상함에 따라 투자자들은 HACK, CIBR, BUG ETF를 주목하는 것이 현명할 것이다.
이미지: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

세계경제포럼(WEF)의 2025년 &#8216;글로벌 리스크 보고서&#8217;는 앞으로의 도전 과제에 대한 냉정한 그림을 보여 준다. <a href="https://www.benzinga.com/topic/world-economic-forum#more-news" target="_blank" rel="noopener">스위스 다보스에서 열린 WEF 연례 회의에서</a> 발표된 이번 설문조사는 지정학적 긴장, 기후 변화, 허위 정보에 대한 리스크를 강조한다.
이러한 리스크는 새로운 기회를 활용하면서 투자를 보호할 수 있는 전략을 요구한다. 오늘은 해당 설문조사에서 언급된 각 글로벌 도전 과제에서 투자자가 순조롭게 항해하는 데 도움이 될 수 있는 몇 가지 ETF를 소개한다.
<h3>무력 분쟁</h3>
WEF 보고서에 따르면 응답자의 23%는 2025년에 가장 시급한 리스크로 국가 기반 무력 분쟁을 꼽았다. 러시아-우크라이나 분쟁과 중동의 불안과 같은 지정학적 긴장이 지속되면서 전 세계의 신뢰가 흔들리고 있다.
이러한 엄중한 상황에서 국방 ETF와 글로벌 보안 ETF가 투자자에게 도움이 될 수 있다. iShares U.S. Aerospace &amp; Defense ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ITA#BATS">ITA</a>)는 군사력에 대한 정부 지출 증가로 혜택을 받을 수 있는 미국 기반 방위 부문 기업에 대한 노출을 제공한다. 또한 0.4%의 운용보수율로 비용 효율적인 옵션이다. 또한 베타가 0.97%이므로 변동성 장세에서 전체 시장보다 위험도가 약간 낮다.
또한 SPDR S&amp;P Kensho Future Security ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FITE#NYSE">FITE</a>)는 사이버 보안 및 물리적 방어를 포함한 글로벌 보안 문제를 해결하는 혁신적인 기업에 중점을 둔다. 주요 보유 종목으로는 비아샛(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>), 록히드 마틴(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LMT#NYSE">LMT</a>) 및 F5 네트웍스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) 등이 있다. 이 펀드는 0.45%의 운용보수율을 자랑한다.
<h3>극한의 날씨</h3>
기후 위기로 인해 홍수, 폭염, 토네이도와 같은 기상 이변의 빈도와 심각성이 심화되고 있다. 환경 리스크가 10년 후를 지배하는 상황에서 탄력적인 투자 전략이 필요한 시점이다.
청정 에너지 ETF는 이러한 글로벌 과제를 활용할 수 있는 유리한 위치에 있다. Invesco Solar ETF(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>)는 엔페이즈 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENPH#NYSE">ENPH</a>)와 퍼스트 솔라(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NYSE">FSLR</a>)와 같은 태양광 에너지 회사에 투자하고 있으며, 이들은 글로벌 탈탄소화 노력으로부터 혜택을 볼 수 있다.
<h3>허위 정보 및 조작된 정보</h3>
WEF는 2년 연속 잘못된 정보와 허위 정보의 폐해가 사회적 불신, 시장 혼란, 양극화 심화를 초래하는 가장 큰 리스크 요소로 지목했다.
많은 기술 기업들이 허위 정보(misinformation)뿐만 아니라 조작된 정보(disinformation)의 확산을 억제하기 위한 노력에 동참하고 있다. 그러나 이러한 위협에 가장 잘 대처하는 기업은 사이버 보안 기업이다. 당연히 <a href="https://www.benzinga.com/25/01/42829188/hack-attack-cybercrime-surge-fuels-demand-for-cybersecurity-etfs" target="_blank" rel="noopener">사이버 보안 부문에 초점을 맞춘 ETF</a>가 유리할 수밖에 없다.
First Trust Nasdaq Cybersecurity ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIBR#NASDAQ">CIBR</a>)는 허위 정보를 부채질하는 사이버 위협에 대응하는 회사들에 초점을 맞추고 있다. 브로드컴(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>), 크라우드스트라이크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRWD#NASDAQ">CRWD</a>), 시스코 시스템즈(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) 같은 사이버 보안 분야의 주요 기업들이 이 펀드의 보유 종목이다.
미디어 ETF인 Communication Services Select Sector SPDR Fund(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>)도 미디어 회사들이 신뢰할 수 있는 콘텐츠 제작 및 디지털 정보 기술에 투자하여 혜택을 받을 수 있으므로 이익을 볼 수 있다.
<h3>격변기에 ETF 투자가 이상적인 이유는?</h3>
작년 9월과 10월에 900명 이상의 글로벌 리스크 전문가, 정책 입안자 및 업계 리더로부터 인사이트를 얻어 WEF의 설문조사 보고서를 작성했다. WEF의 보고서가 강조하는 단기적 리스크에는 사회 양극화, 사이버 스파이 활동, 환경오염, 불평등 등이 있다.
이러한 격동의 시기에 투자자들은 시장에서 주저하는 대신 투자를 헤지하려고 한다. ETF는 글로벌 불확실성 속에서 투자자들이 여러 부문과 지역에 걸쳐 포트폴리오를 다각화할 수 있는 유연하고 비용 효율적이며 관심사에 특화된 상품으로 각광받고 있다.
마시 맥레넌 유럽(Marsh McLennan Europe)의 캐롤리나 클린트는 CNBC와의 인터뷰에서 이렇게 말했따. "우리는 지금 경제적 긴장이 고조되는 시대를 헤쳐나가고 있다고 생각한다. 그리고 파편화는 이론적인 문제가 아니라는 점을 인식해야 한다고 본다. 오늘날 우리가 직면해야 할 문제다. 그 결과 거래 환경이 더욱 복잡하고 불확실해졌다."
글로벌 도전 과제에 맞춘 ETF로 탄력적인 포트폴리오를 구축하면 투자자들이 2025년을 힘차게 나아가는 데 도움이 될 것이다.
사진: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

중국 정부의 지원을 받는 해커들이 미국의 중요한 <a href="https://www.benzinga.com/topic/infrastructure" target="_blank" rel="noopener">인프라</a>에 &#8216;대혼란&#8217;을 일으킬 수 있는 지능형 공격을 조율하고 있다고 미국 연방수사국(FBI) 국장인 크리스토퍼 레이(Christopher Wray)가 밝혔다.
그는 목요일 내슈빌에서 열린 현대 분쟁에 관한 서밋(Summit on Modern Conflict)에서 참석자들에게 &#8220;수처리 시설과 에너지 그리드부터 교통 및 정보 기술에 이르기까지 모든 것이 우리 사회의 중추를 형성한다&#8221;고 <a href="https://www.fbi.gov/news/speeches/director-wrays-remarks-at-the-vanderbilt-summit-on-modern-conflict-and-emerging-threats" target="_blank" rel="noopener">말했다</a>.
그런 것들이 공격을 받으면 어떻게 될까? 레이는 그러한 시나리오가 언제든지 발생할 수 있다고 경고했다.
그는 &#8220;중국은 &#8216;그냥&#8217; 터무니없는 절도 캠페인 그 이상을 위해 대규모 해킹 기업(50대 1)을 포지셔닝하고 있다&#8221;고 덧붙였다. &#8220;그것은 그 질량과 숫자를 사용하여 선택한 시간에 우리의 중요한 인프라에 물리적으로 큰 피해를 입힐 수 있는 능력을 스스로 부여하는 것이다.&#8221;
레이는 민간 기업들에게 &#8220;경계를 표명&#8221;하고 &#8220;적들이 우리를 상대로 무엇을 하고 있거나 무엇을 준비하고 있는지에 대한 중요한 정보를 생성하는 중앙 방어 역할&#8221;을 수행할 것을 촉구했다.
<h3 class="wp-block-heading">주목해야 할 3개의 OT 스타트업</h3>
웨드부시의 애널리스트 타즈 코우잘기(Taz Koujalgi)에 따르면 레이의 발언은 &#8220;전혀 과장적이지 않다&#8221;. 이는 OT(운영 기술, operational technology) 전문가들의 중요성이 커지고 있음을 강조한다.
아래 3개 기업들을 살펴보자:
<ul>
<li>드라고스(Dragos Inc.)는 &#8216;OT 분야의 선도적인 개척자 중 하나&#8217;라고 코우잘기가 Benzinga에게 말했다. 메릴랜드 주 하노버에 본사를 둔 이 회사는 지금까지 벤처 캐피털로 약 4억 4천만 달러를 모았다.</li>
<li>현재까지 6억 3,500만 달러 이상의 자금을 조달한 뉴욕 소재 클래로티(Claroty)는 지난달 추가로 1억 달러의 지원을 <a href="https://claroty.com/press-releases/claroty-secures-usd100-million-in-strategic-growth-financing" target="_blank" rel="noopener">확보</a>했다.</li>
<li>그리고 샌프란시스코에 본사를 둔 노조미 네트웍스(Nozomi Networks)도 지난달 신규 자금 1억 달러를 확보해 총 2억 6천만 달러가 넘었다.</li>
</ul>
오늘날 대부분의 &#8220;보안 지출&#8221;은 전통적인 IT 인프라 공간에서 발생한다고 코우잘기가 말했다. &#8220;그러나 실제 기반 시설인 파이프라인, 전력망 및 수처리 공장은 투자 및 보안 지출 측면에서 상당히 뒤처져 있다.&#8221;
그리고 벤처 지원이 전반적으로 부족하다는 점을 고려하면 OT 하위 부문에서 자본을 조달하는 것은 특히 어렵다.
또 다른 어려움은 이러한 유형의 기반 시설 공격이 &#8220;꽤 새로운&#8221; 현상이며 &#8220;빠르게 변화하고 있다&#8221;는 점이다.
매일 새로운 소프트웨어가 만들어지고 있으며 악의적인 행위자들이 일상적으로 해당 소프트웨어에서 허점을 발견함에 따라 5년 전의 코드는 쓸모 없게 될 위험에 처해 있다고 코우잘기가 설명했다.
말하자면, &#8220;나쁜 놈들의 속도에 맞추기가 어렵다&#8221;는 것이다.
<h3 class="wp-block-heading">나쁜 놈들은 누구인가?</h3>
우리는 이미 2023년에 마이크로소프트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>)와 서방 정보 기관들의 보안 분석가들이 &#8216;볼트 타이푼'(Volt Typhoon)&#8216;으로 알려진 국가 후원의 중국 해킹 그룹이 <a href="https://www.benzinga.com/government/23/05/32573948/microsoft-blames-chinese-hackers-for-spying-on-critical-american-infrastructure-and-guam">다양한 미국의 핵심 기반 시설 기관을 스파이했다는 사실</a>을 밝혀냈다는 것을 알고있다.
중국과 미국은 일상적으로 서로를 감시하고 있다. 그러나 분석가들은 이번 사건이 미국의 중요 인프라에 대한 중국의 가장 광범위한 사이버 스파이 활동 중 하나였다고 말한다.
중국은 지난 3월 이러한 사이버 공격 주장을 &#8216;순수한 정치적 책략&#8217;이라고 <a href="https://www.scmp.com/video/china/3256907/china-denies-accusations-state-sponsored-hacking-us-uk-and-new-zealand" target="_blank" rel="noreferrer noopener">일축</a>했다.
중국 외교부의 린 지안 대변인은 &#8220;미국이 <a href="https://www.benzinga.com/government/22/09/28959768/china-claims-us-took-control-of-telecom-network-post-space-research-university-hack" target="_blank" rel="noopener">중국에 대한 자체 사이버 공격</a>을 그만두도록 요청한다&#8221;고 말했다.
하지만 레이가 말한 대로, 볼트 타이푼은 &#8220;지속적인 PRC 접근 &#8230; 그들은 우리 네트워크 안에 숨어들어 &#8216;리빙 오프 더 랜드(living-off-the-land)&#8217;라고 알려진 전술을 사용했다. &#8212; 즉, 피해자 네트워크에 이미 존재하는 내장 도구를 악용하여 악의적인 작업을 수행했다. 네트워크 방어자가 사용되고 있을 것으로 예상하는 도구들이기 때문에 의심을 불러일으키지 않는다. 동시에 그들은 보트넷을 운영하여 그들의 악의적인 활동과 그것이 중국에서 온 것임을 더욱 숨기고 있었다. 이 모든 것은 중국 정부에게 치명적인 타격을 가할 수 있는 적절한 순간을 기다릴 능력을 부여하기 위한 목표로 이루어졌다.&#8221;
&#x2A;&#x2A; 참고: living-off-the-land란 자급자족식 공격으로 타깃 시스템에 미리 설치되어 있는 도구를 활용하여 공격을 하는 행위.
그리고 그것은 단지 중국뿐만 아니다. 2021년에 콜로니얼 파이프라인(Colonial Pipeline)에 대한 사이버 공격의 책임이 있는 다크사이드(DarkSide)라는 해커 그룹도 있었고, 이로 인해 <a href="https://www.benzinga.com/news/21/05/21026280/colonial-pipeline-hackers-stole-data-on-thursday-ahead-of-shutdown-bloomberg" target="_blank" rel="noopener">완전한 폐쇄</a>가 발생했다.
같은 해, 삼엄한 경비를 받고 있는 이란의 나탄즈(Natanz) 공장에 사이버 공격이 발생했다. 이번 중단으로 인해 테헤란의 핵 프로그램이 9개월 지연된 것으로 알려졌다. 미국과 이스라엘 모두 사보타주 캠페인으로 여겨지는 행위에 관여했다는 사실을 인정하지 않았다.
ETF도 고려해보자: 여기 주목할만한 사이버 보안 ETF 5개가 있다:
<ul>
<li>Amplify ETF Trust Amplify Cybersecurity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HACK#NYSE">HACK</a>)</li>
<li>First Trust NASDAQ Cybersecurity ETF(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CIBR#NASDAQ">CIBR</a>)</li>
<li>iShares Cybersecurity and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IHAK#NYSE">IHAK</a>)</li>
<li>WisdomTree Cybersecurity Fund (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WCBR#NASDAQ">WCBR</a>)</li>
<li>Global X Cybersecurity ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BUG#NASDAQ">BUG</a>)</li>
</ul>
이미 읽은 내용: <a href="https://www.benzinga.com/news/24/04/38214476/russian-government-linked-hackers-stole-federal-email-correspondence-with-microsoft-cisa">러시아 정부 연계 해커들이 미국 국방부와 마이크로소프트와의 연방 이메일 통신을 도난</a>

中 해커가 美의 주요 인프라에 '대혼란'을 일으킬  수 있다고 FBI가 경고 - 주목해야 할 스타트업 3곳

Comments

First Trust NASDAQ Cybersecurity ETF

뉴스

에 대한 최신 뉴스 First Trust NASDAQ Cybersecurity ETF (NASDAQ:CIBR)

목요일, 3월 20, 2025

목요일, 1월 16, 2025

일요일, 4월 21, 2024

뉴스

파트너 / 기고자

벤징가 글로벌